Journal Review in Surgical Oncology: Neuroendocrine Tumors of the Small Bowel

Behind The Knife: The Surgery Podcast

Science, Health & Fitness, Medicine, Education

4.8 • 1.4K Ratings

🗓️ 23 June 2025

⏱️ 31 minutes

🔗️ Recording | iTunes | RSS

🧾️ Download transcript

Summary

Join the Behind the Knife Surgical Oncology Team as we discuss the two key studies investigating optimal management strategies of neuroendocrine tumors of the small bowel.

Hosts:
- Timothy Vreeland, MD, FACS (@vreelant) is an Assistant Professor of Surgery at the Uniformed Services University of the Health Sciences and Surgical Oncologist at Brooke Army Medical Center
- Daniel Nelson, DO, FACS (@usarmydoc24) is Surgical Oncologist/HPB surgeon at Kaiser LAMC in Los Angeles.
- Connor Chick, MD (@connor_chick) is a 2nd Year Surgical Oncology fellow at Ohio State University.
- Lexy (Alexandra) Adams, MD, MPH (@lexyadams16) is a 1st Year Surgical Oncology fellow at MD Anderson.
- Beth (Elizabeth) Barbera, MD (@elizcarpenter16) is a PGY-6 General Surgery resident at Brooke Army Medical Center

Learning Objectives:
In this episode we review two important papers that discuss optimal management strategies of neuroendocrine tumors (NET) of the small bowel. The first paper by Singh and colleagues discusses the NETTER-2 trial investigating the role of radioligand therapy for NET as a first-line treatment. The second article by Maxwell et all challenges surgical dogma regarding optimal debulking cutoffs for debulking of NET.

Links to Papers Referenced in this Episode:
1. Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz PL, Chasen B, Tafuto S, Lastoria S, Capdevila J, García-Burillo A, Oh DY, Yoo C, Halfdanarson TR, Falk S, Folitar I, Zhang Y, Aimone P, de Herder WW, Ferone D; all the NETTER-2 Trial Investigators. [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet. 2024 Jun 29;403(10446):2807-2817. doi: 10.1016/S0140-6736(24)00701-3. Epub 2024 Jun 5. PMID: 38851203. https://pubmed.ncbi.nlm.nih.gov/38851203/

2. Maxwell JE, Sherman SK, O'Dorisio TM, Bellizzi AM, Howe JR. Liver-directed surgery of neuroendocrine metastases: What is the optimal strategy? Surgery. 2016 Jan;159(1):320-33. doi: 10.1016/j.surg.2015.05.040. Epub 2015 Oct 9. PMID: 26454679; PMCID: PMC4688152. https://pubmed.ncbi.nlm.nih.gov/26454679/

Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.

If you liked this episode, check out our recent episodes here: https://app.behindtheknife.org/listen

Transcript

Click on a timestamp to play from that location

0:00.0	Behind the Night, the Surgery podcast, relevant and engaging content designed to help you Behind the Night.
0:24.3	This is Jason here.
0:25.5	If you're prepping for the complex general surgical oncology boards
0:28.3	or just looking to level up your surge oncology game,
0:30.8	you need to check out our surgical oncology board review.
0:33.6	This isn't some lame review with just flashcards and outlines.
0:37.1	We've created comprehensive high-yield scenarios covering the most tested diseases,
0:41.8	plus expert commentary, and updated guidelines that actually stick and are proven to help you pass the boards.
0:47.5	Breast, pancreas, sarcoma, you name it, we've got you covered.
0:50.9	Available on our app, so you can review anytime, anywhere.
0:55.4	Group discounts are available. Enjoy the episode and dominate the day. Hi, everyone, and welcome back to another journal
1:01.4	article review with your surgical oncology team. I'm Elizabeth Barbera. I'm a six-year resident
1:06.5	at Berkermanian Medical Center. I'm Connor Chick. I'm a surgical oncology fellow at Ohio State.
1:11.7	I'm Lexi Adams. I'm a surgical oncology fellow, M.D. Anderson.
1:15.2	I'm Tim Breland. I'm a surgical oncology staff of Brook Army Medical Center.
1:19.4	Unfortunately, Dr. Nelson couldn't make it this time around, but we're excited to have him
1:23.7	back for our next episode.
1:25.4	We're also thrilled to be signing on again with the BTK team for an additional two years
1:30.1	of great surgical oncology content.
1:32.5	So keep an ear out for new episodes with some new members as well.
1:35.6	Anyway, let's get started with today's episode, which we're all pretty excited about.
1:39.5	We highly recommend you guys check out our most recent clinical challenges episode, which was
	...

Please login to see the full transcript.

Previous episode | Next episode

Disclaimer: The podcast and artwork embedded on this page are from Behind The Knife: The Surgery Podcast, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of Behind The Knife: The Surgery Podcast and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.